2015

Empagliflozin in the Treatment of Type 2 Diabetes: Evidence to Date

Jay H. Shubrook
*Touro University California, jay.shubrook@tu.edu*

Babak Baradar Bokaie

Sarah E. Adkins

Follow this and additional works at: https://touroscholar.touro.edu/tuccom_pubs

Part of the Endocrine System Commons, Nutritional and Metabolic Diseases Commons, and the Therapeutics Commons

Recommended Citation


This Article is brought to you for free and open access by the College of Osteopathic Medicine at Touro Scholar. It has been accepted for inclusion in College of Osteopathic Medicine (TUC) Publications and Research by an authorized administrator of Touro Scholar. For more information, please contact carrie.levinson2@touro.edu.
Empagliflozin in the treatment of type 2 diabetes: evidence to date

Jay H Shubrook¹
Babak Baradar Bokaie²
Sarah E Adkins³

¹Primary Care Department, Clinical Research and Diabetes Services, Touro University College of Osteopathic Medicine, Vallejo, CA, USA; ²The Diabetes Institute at Ohio University, Athens, OH, USA; ³Pharmacy Practice and Administration, College of Pharmacy, Ohio State University, Athens, OH, USA

Abstract: In the last decade, researchers have gained a greater understanding of the pathophysiologic mechanisms of type 2 diabetes as a chronic and progressive disease. One of the more recent treatment targets is the kidney. The kidneys become maladaptive in diabetes by increasing the reabsorption of glucose above the normal physiologic renal threshold. This discovery has led to the development of the sodium/glucose cotransporter 2 inhibitors (SGLT2). These agents readjust the renal threshold for glucose reabsorption to a lower level and decrease glucose reabsorption, while increasing urinary glucose when the glucose is above the renal threshold and subsequently lowering plasma glucose. The mechanism of action of the SGLT2 inhibitors is insulin independent, which makes them a novel treatment of diabetes. At the time of preparation of this manuscript, there were three SGLT2 inhibitors available in the US. This manuscript focuses on empagliflozin, the newest SGLT2 inhibitor, the trials in its development, and the clinical data available to date. Further, the authors propose future applications of empagliflozin, including in the treatment of type 1 diabetes, and its potential role in renoprotection.

Keywords: SGLT-2 inhibitors, empagliflozin, type 2 diabetes, kidneys, type 1 diabetes, glucosuria

Introduction

Type 2 diabetes mellitus (T2DM) has become a global pandemic. It is now estimated that nearly 387 million people have diabetes globally.¹ Rates in developing countries are increasing due to the changes in rates of obesity and inactivity. Deaths from diabetes are projected to increase 50% worldwide by 2025. Eighty percent of these deaths will occur in low and middle income countries.² T2DM is a complex and progressive disease. Once thought of as only a disease of insulin resistance, it is now believed that there are at least eight pathologic processes that lead to type 2 diabetes.³ These include abnormal β-cell insulin secretion, excessive α-cell glucagon production, abnormal incretin effect, insulin resistance at the peripheral tissues, increased hepatic glucose production, increased lipolysis, neurotransmitter dysfunction, and abnormal renal handling of hyperglycemia.³ Knowledge of these pathophysiologic mechanisms is critical in the development and use of targeted treatments that have complementary mechanisms of action.

Insulin resistance is usually maximal at the time a person is diagnosed with T2DM. β-cell dysfunction and failure become prominent defects in this progressive disease. As T2DM is a multisystemic and progressive disease, no single therapy is adequate for long-term control. Treatment must be multifactorial, and combination therapy is often necessary. Most of the current available treatments are insulin “centric”, meaning that they need insulin production to provide therapeutic benefit. These therapies only have a therapeutic effect as long as there is measurable insulin production. One of the newly discovered pathophysiologic processes that can be treated is increased renal glucose reabsorption that occurs in diabetes.⁴ This treatment is novel because...
the kidney has not been a therapeutic target previously, and the mechanism of action is independent of insulin.

**Introduction to renal glucose physiology**

Plasma glucose is usually maintained in a relatively narrow range between 70 and 160 mg/dL (3.9 and 8.9 mmol/L). This involves a delicate balance between glucose production (liver and kidney), intestinal absorption, renal reabsorption, and glucose utilization in tissues around the body. In a normal healthy adult, kidneys can filter 160–180 g of glucose/d (mean glucose 100 mg/dL ×180 L/d).5,6 In euglycemic people, essentially all the filtered glucose is reabsorbed in the proximal convoluted tubule allowing the glucose to remain in circulation. The normal filtered glucose load in a person without diabetes is approximately 125 mg/min, but can rise when the ambient glucose rises or if the glomerular filtration rate increases. The maximum renal threshold for glucose reabsorption occurs when the serum glucose is approximately 180–200 mg/dL. In these individuals, when the glucose exposure to the kidney exceeds ≥200 mg/dL (11.0 mmol/L), no additional glucose is reabsorbed and the excessive glucose is excreted in the urine.6

Glucose reabsorption is mediated by the sodium/glucose cotransporter (SGLT) proteins. This process is independent of insulin.7 The great majority of the filtered glucose (90%) is reabsorbed in the first segment of the proximal convoluted tubule by SGLT2. SGLT2 is a low affinity but high capacity transporter.8 The remaining filtered glucose (10%) is removed from the filtrate by SGLT1 in the distal aspect of the proximal convoluted tubule. SGLT1 is a high-affinity and low-capacity transporter.8 This mechanism allows for conservation of calories.

There are a number of SGLT proteins expressed throughout the body.4 SGLT1 is expressed in the small intestine and helps to regulate glucose and galactose absorption in the kidney as mentioned before. People who do not have functioning SGLT1 will suffer from significant gastrointestinal (GI) complications including severe diarrhea, while those without functioning SGLT2 appear to live normal lives despite increased glucosuria. The SGLT2 inhibitors work on the SGLT1 and SGLT2 proteins. Therefore, high selectivity toward SGLT2 may be pharmacologically beneficial. Dual blockade may provide an even greater therapeutic effect, but it will need to be balanced with the GI effects of SGLT1 blockade (Figure 1).

**Renal physiology in type 2 diabetes**

People with T2DM routinely experience both fasting and postprandial hyperglycemia, which is a result of a number of maladaptive physiological responses that include exaggerated hepatic and renal glucose production, impaired insulin secretion, and inefficient glucose uptake.3 Recently, the kidney’s maladaptive response to chronic hyperglycemia has become a treatment target in diabetes.

Normal renal physiology dictates that all filtered glucose is reabsorbed. However, if the plasma glucose levels rise above 200 mg/dL (11 mmol/L) as seen in diabetes, some glucose is excreted in the urine. As shown in diabetic mice, there is upregulation of SGLT2. This might contribute to the increased plasma glucose threshold before any glucose is seen in the urine.9

However, in mouse models of diabetes mellitus, there is upregulation of SGLT2 in response to chronic hyperglycemia, allowing more glucose reabsorption.10 Furthermore, there is also an increase in SGLT protein expression in diabetes.11 These combine to potentially increase the maximum renal glucose threshold which contributes to more glucose reabsorption, which maintains plasma hyperglycemia (Figure 2).

**Early attempts to address abnormal renal physiology via SGLT proteins**

More than 100 years ago, it was identified that a botanical agent could induce glucosuria. The active ingredient was later identified as phlorizin, a substance found in the bark of apple trees.12,13 Unfortunately, phlorizin had a number of significant limitations that made it unviable as a pharmacologic treatment. It had little selectivity for SGLT2 over SGLT1. The SGLT1 activity resulted in significant GI side effects. Further, phlorizin has an O-glucosidase which makes it susceptible to degradation by the β-glucosidase in the intestine, so it required IV dosing.14

Empagliflozin is structurally similar to phlorizin but with some important differences. It has a C-glucoside with a carbon–carbon bond between the glucose and aglycone moiety. This makes it resistant to degradation in the GI tract, allowing it to be orally administered.15 Further, because empagliflozin (EMPA) is highly selective for SGLT2 (>2,500-fold), it is less likely to have GI side effects.7

The glucosuric effects of SGLT2 blockade raised early concerns about the safety of chronic high glucose levels in the renal tubules and in the urine. In familial renal glucosuria, people have nonfunctioning SGLT2 proteins from a mutation of the SLC5A2 gene that encodes SGLT2. These patients have chronic glucosuria even in the face of normoglycemia. Individuals with this condition rarely suffer from glucose-related problems and have no known renal problems. This mechanism allows for conservation of calories.
Empagliflozin update

Figure 1 Physiology of glucose reabsorption in the proximal convoluted tubule.


Abbreviations: GLUT, glucose transporter; PT, proximal tubule; KCNE1, potassium voltage-gated channel Isk-related family member 1; KCNQ1, potassium voltage-gated channel KQT-like subfamily member 1; SGLT, sodium-dependent glucose transporter.

tubular dysfunction and typically do not report increased genitourinary infections.16

Conversely, loss of function of SGLT1 from a mutation of SLC5A1 results in little to no glucosuria but significant GI symptoms because of the glucose–galactose malabsorption that results in watery diarrhea and potentially dehydration.17 Thus, preferential targeting SGLT2 proteins (rather than SGLT1) with pharmacologic intervention is preferable.

SGLT2 inhibitors

The SGLT2 inhibitors are a new drug class that address hyperglycemia by reducing renal glucose reabsorption, increasing urinary glucose excretion, and consequentially reducing serum glucose levels.18,19 The SGLT2 inhibitors work independent of insulin (both secretion and sensitivity), which makes this class novel and potentially complementary to most current diabetes therapies.

There are currently three SGLT2 inhibitors available in the US. Canagliflozin was approved by the US Food and Drug Administration (FDA) in March 2013 (FDA news release 2013),20 dapagliflozin in January 2014, and EMPA in August of 2014.21 All of these agents are potent competitive inhibitors of the SGLT2 protein, but dapagliflozin and EMPA are highly selective for SGLT2, while canagliflozin has dual blockade of SGLT1 and SGLT2. Of the three commercially available SGLT2 inhibitors, EMPA has the highest selectivity for SGLT2 (>2,500-fold) compared to SGLT1.22 The chemical structure for EMPA is shown in Figure 3.

Preclinical studies

Preclinical studies showed that EMPA is a competitive inhibitor of the SGLT2, has high specificity to SGLT2, and has a half-life of approximately 60 minutes. Early cell line studies demonstrated that EMPA is a potent inhibitor of SGLT2 and has >2,500-fold sensitivity for inhibition of SGLT2 vs SGLT1.23 Subsequent rodent studies showed that EMPA reduced blood glucose in a dose-dependent manner by increasing urinary glucose excretion.22 In one 5-week
trial, EMPA reduced HbA1c levels by 0.3% (1 mg/kg) and 1.1% (3 mg/kg).24

Human Phase I studies
A single dose of EMPA was studied in 72 healthy males.25 Subjects were randomized to placebo or a dose of EMPA between 0.5 and 800 mg. EMPA was quickly absorbed with a maximum plasma concentration at approximately 1.5–2.1 hours, with drug exposure proportional to the dose administered. EMPA had a biphasic decline in concentration in the decay phase, with a terminal half-life of 8.6–13.1 hours.22 In these studies, the urinary glucose excretion increased to a maximum at the 50 mg dose, significantly higher than placebo.24 Food and postprandial state had no effect on drug absorption, and glucosuria was similar after meals in these healthy subjects. All side effects were similar to placebo (headaches, GI, and nervous system disorders) and were not dose dependent. One hypoglycemic event was reported (glucose 53 mg/dL [2.9 mmol/L]) during a 3-hour glucose tolerance test.

Another series of Phase I trials tested EMPA 1–100 mg in 48 healthy Japanese men.26 In these studies, EMPA was rapidly absorbed with a maximum concentration at around 1.25–2.5 hours, with drug exposure and clearance relative to the dose administered. EMPA exposure was approximately 1.5 times higher in this study possibly due to differences in body weight between the population studies. The urinary glucose clearance was dose dependent as well. EMPA was
well tolerated (mild side effects, not dose dependent), and no hypoglycemia was reported.

Finally, the pharmacokinetic (PK) and pharmacodynamics (PDs) profiles of EMPA were determined after the first dose on day 1 and at steady state dosing on day 28. EMPA was rapidly absorbed with peak concentration at 1.5 hours. Clearance was biphasic with a range of 13.2–16.5 hours. Oral clearance showed linear PKs in terms of time. Eighteen percent of the medication was excreted in the urine unchanged. The urinary glucose excretion was dose dependent. Compared to baseline, urinary glucose excretion increased to 74 g in the 10 mg dose, 90 g in the 25 mg dose, and 81 g in the 100 mg dose. There was essentially no change in urinary glucose excretion in the placebo group. Urinary glucose excretion remained constant throughout the study. No significant changes in urine volume were reported. There were significant reductions in fasting and post oral glucose tolerance test glucose readings on day 28 compared to placebo. A nonsignificant reduction in HbA1c was seen in the EMPA groups at 28 days (Table 1).

## Phase II trials

A study evaluated the safety, tolerability, and PK/PD in 78 people with type 2 diabetes.37 Subjects were randomized to EMPA (10, 25, 100 mg) or placebo. Weighted randomization was completed for the 100 mg dose (2× other groups) to assess the safety of this dose. The plasma concentration and urinary glucose excretion were dose dependent. Urinary glucose excretion remained constant throughout the trial compared to no increase in the placebo-treated group. Side effects were similar in the treatment arms, with the most common adverse effects being pollakiuria (10.3%), nasopharyngitis (9.0%), constipation (9.0%), and headache (7.7%). Urinary-related adverse effects were more common in the EMPA groups.

### Clinical benefits of empagliflozin in Phase III trials

Empagliflozin has been studied as a monotherapy and in combination therapy for type 2 diabetes. A1c reduction with EMPA 10 mg (−0.66%) or 25 mg (−0.78%) was statistically superior to that observed with placebo (0.08%) when given as monotherapy.35 A1c reduction with EMPA 10 and 25 mg was similar to A1c reduction with sitagliptin 100 mg.33

In another study, investigators randomized 408 treatment naïve (or 4-week washout) subjects with type 2 diabetes to EMPA 25 mg, metformin, or placebo. The overall mean A1c was 7.9%±0.8% at entry. All EMPA doses had significant A1c reductions compared to placebo (placebo +0.1%; EMPA 5 mg, −0.4%; 10 mg, −0.5%; 25 mg, −0.6%; all P<0.0001) and showed similar reduction as compared with metformin (−0.7%).

A trial evaluated the PK/PD of a single dose of 50 mg of EMPA in 40 patients with various levels of renal impairment. The peak concentration was similar to previous studies, but the total plasma exposure and maximum concentration were slightly elevated in those with advanced renal impairment. In this study, the greater the renal impairment, the lower the urinary glucose excretion.

There was some initial concern about hepatic safety in early studies with dapagliflozin. In a similar set of studies with EMPA (as already mentioned), there did not appear to be any dose adjustment needed in people with mild, moderate, or severe hepatic impairment.31 These studies are summarized in Table 2.

Some small studies have reported an increase in endogenous glucose production with SGLT2 inhibitors including EMPA.32–34 The elevated hepatic glucose production appears to be a compensatory response to support normal plasma glucose levels in the presence of sustained urinary glucose excretion. The plasma glucagon/insulin ratio is a regulator of hepatic glucose production and so the increase in glucagon could explain the rise in hepatic glucose production observed with SGLT2 inhibition.30 Overall, glucose levels are still decreased despite the increase in glucose production. Further investigation is needed to determine the long-term significance of this physiologic response and optimal therapeutic approach.

### Notes

- Abbreviations: AUC, area under concentration–time curve; Cmax, maximum plasma concentration; CLR, renal clearance; Fe, fraction of dose that was excreted unchanged in urine; qd, once daily; SD, standard deviation; ss, steady state; t1/2, terminal half-life in plasma; tmax, time to maximum plasma concentration.

---

**Table 1 Summary of key pharmacokinetic parameters of empagliflozin 10 and 25 mg at steady state after oral dosing**

<table>
<thead>
<tr>
<th>Pharmacokinetic parameters</th>
<th>Empagliflozin dose</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>10 mg qd (n=8)</td>
</tr>
</tbody>
</table>

| AUCss | 2.030 (362) | 4.990 (1.080) |
| Cmax | 283 (90.1)  | 630 (106)     |
| t1/2 (h) | 1.5 (1.0–2.0) | 2.0 (0.7–4.2) |
| tmax (h) | 14.3 (2.4)   | 10.7 (2.1)    |
| CLR, t, ss (mL/min) | 34.4 (7.9)  | 23.5 (8.7)    |

**Notes:** Data are mean (SD) unless otherwise indicated. *Median (range) is denoted. Reprinted from McGill J. The SGLT2 inhibitor empagliflozin for the treatment of type 2 diabetes mellitus: a bench to bedside review. Diabetes Ther. 2014;5:43–63.15**
Nearly two-thirds of the subjects in this study entered the extension phase of the study for an additional 52 weeks for a total of 76 weeks. The placebo-subtracted A\textsubscript{1c} reductions at 76 weeks were 0.78% for EMPA 10 mg, 0.89% for EMPA 25 mg, with persistent weight loss of 1.8 kg with 10 mg of EMPA and 2.0 kg for 25 mg of EMPA and SBP reductions of 3.4 mmHg in both the 10 and 25 mg arms of EMPA.\textsuperscript{36}

As add-on therapy to metformin, EMPA 25 mg has been shown to be statistically superior to glimepiride in a 104-week study.\textsuperscript{37} The A\textsubscript{1c} reduction was 0.66% with EMPA and 0.55% with glimepiride. Weight and blood pressure were reduced with EMPA (−3.1 kg, −3.1 mmHg), and these changes were not seen with glimepiride (−1.3 kg, +2.1 mmHg).

When EMPA was given in combination with other medications, there were significant improvements in HbA\textsubscript{1c}. Table 3 provides an overview of EMPA with metformin\textsuperscript{38,39} metformin plus a sulfonylurea,\textsuperscript{38} pioglitazone or pioglitazone plus metformin,\textsuperscript{40} or multidose insulin with or without metformin.\textsuperscript{41}

Table 2 Empagliflozin pharmacokinetics after administration of a single 50 mg dose in patients with renal or hepatic impairment

<table>
<thead>
<tr>
<th>Impairment severity</th>
<th>Total plasma exposure AUC\textsubscript{ss} (nmol h/L)</th>
<th>C\textsubscript{max} ss (nmol/L)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Renal impairment study\textsuperscript{37}</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mild (n=9)</td>
<td>118.2% (96.2, 145.4)</td>
<td>118.8% (93.6, 150.8)</td>
</tr>
<tr>
<td>Moderate (n=7)</td>
<td>119.9% (96.3, 149.5)</td>
<td>102.3% (79.3, 131.9)</td>
</tr>
<tr>
<td>Severe (n=8)</td>
<td>166.3% (134.4, 205.7)</td>
<td>120.7% (94.4, 154.3)</td>
</tr>
<tr>
<td>Failure/ESRD (n=8)</td>
<td>148.3% (119.9, 183.4)</td>
<td>103.8% (81.2, 132.6)</td>
</tr>
<tr>
<td>Hepatic impairment study\textsuperscript{38}</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mild (n=8)</td>
<td>123.15% (98.9, 153.4)</td>
<td>103.8% (82.3, 131.0)</td>
</tr>
<tr>
<td>Moderate (n=8)</td>
<td>146.97% (118.0, 183.0)</td>
<td>123.3% (97.7, 155.6)</td>
</tr>
<tr>
<td>Severe (n=8)</td>
<td>174.70% (140.3, 217.6)</td>
<td>148.4% (117.7, 187.2)</td>
</tr>
</tbody>
</table>

Notes: For both studies, values are adjusted GMR (impaired/normal group), with 90% CI for adjusted GMR. Reproduced from McGill J. The SGLT2 inhibitor empagliflozin for the treatment of type 2 diabetes mellitus: a bench to bedside review. Diabetes Ther. 2014;5:43–61.\textsuperscript{15}

Abbreviations: AUC, area under the concentration–time curve; CI, confidence interval; C\textsubscript{max} ss, maximum plasma concentration at steady state; ESRD, end-stage renal disease; GMR, geometric mean ratio.

As add-on therapy to metformin, EMPA 25 mg has been shown to be clinically important in that hyperuricemia has been identified as an independent risk factor for cardiovascular disease.\textsuperscript{42}

EMPA was also studied in people with moderate renal insufficiency. EMPA 25 mg resulted in an adjusted mean placebo subtracted A\textsubscript{1c} change of −0.42% at week 24 in patients with estimated glomerular filtration rate (eGFR) ≥30 to <60 mL/min/1.73 m\textsuperscript{2}.\textsuperscript{43} In patients with stage 2 and 3 chronic kidney disease, EMPA resulted in significant reductions of A\textsubscript{1c}, body weight, and SBP compared with placebo after 52 weeks.\textsuperscript{43}

Results from these EMPA studies are consistent with results seen from other agents within the class. A systematic review and meta-analysis of clinical trials comparing an SGLT2 inhibitor with placebo (45 studies, n=11,232) or an active comparator (13 studies, n=5,175) reported improved glycemic control, reduced body weight, and reduced blood pressure with SGLT2 inhibitor therapy.\textsuperscript{44}

Safety of empagliflozin

The most frequently occurring adverse events with EMPA are urinary tract infections (7.6% with placebo vs 9.3% and 7.6% with EMPA 10 and 25 mg, respectively) and genital mycotic infections (in female patients: 1.5% with placebo vs 5.4% and 6.4% with EMPA 10 and 25 mg, respectively).\textsuperscript{23} Adverse events related to osmotic diuresis and volume contraction
Table 3 Efficacy and safety of EMPA in randomized, double-blind Phase III trials of patients with type 2 diabetes mellitus

<table>
<thead>
<tr>
<th>Study</th>
<th>Regimen and duration</th>
<th>Efficacy</th>
<th>Safety</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>A1C (%)</td>
<td>Body weight (kg)</td>
</tr>
<tr>
<td><strong>Monotherapy</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Roden et al³⁵</td>
<td>EMPA 10 mg (n=224)</td>
<td>−0.66</td>
<td>−2.26</td>
</tr>
<tr>
<td></td>
<td>EMPA 25 mg (n=87)</td>
<td>−0.78</td>
<td>−2.48</td>
</tr>
<tr>
<td></td>
<td>PBO (n=228)</td>
<td>0.08</td>
<td>−0.33</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Combination therapy</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Häring et al³⁷</td>
<td>MET + SU + one of:</td>
<td>−0.82</td>
<td>−2.16</td>
</tr>
<tr>
<td></td>
<td>EMPA 10 mg (n=225)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>EMPA 25 mg (n=216)</td>
<td>−0.77</td>
<td>−2.39</td>
</tr>
<tr>
<td></td>
<td>PBO (n=225)</td>
<td>−0.17</td>
<td>−0.39</td>
</tr>
<tr>
<td>Häring et al³⁷</td>
<td>MET + one of:</td>
<td>−0.70</td>
<td>−2.08</td>
</tr>
<tr>
<td></td>
<td>EMPA 10 mg (n=217)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>EMPA 25 mg (n=213)</td>
<td>−0.77</td>
<td>−2.46</td>
</tr>
<tr>
<td></td>
<td>PBO (n=207)</td>
<td>−0.13</td>
<td>−0.45</td>
</tr>
<tr>
<td>Ridderstråle et al³⁹</td>
<td>MET + one of:</td>
<td>−0.66</td>
<td>−3.1</td>
</tr>
<tr>
<td></td>
<td>EMPA 25 mg (n=765)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>GLIM 1–4 mg (n=780)</td>
<td>−0.55</td>
<td>1.3</td>
</tr>
<tr>
<td></td>
<td>104 weeks</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kovacs et al⁴²</td>
<td>PIO + MET + one of:</td>
<td>−0.59</td>
<td>−1.62</td>
</tr>
<tr>
<td></td>
<td>EMPA 10 mg (n=165)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>EMPA 25 mg (n=168)</td>
<td>−0.72</td>
<td>−1.47</td>
</tr>
<tr>
<td></td>
<td>PBO (n=165)</td>
<td>−0.11</td>
<td>0.34</td>
</tr>
<tr>
<td></td>
<td>24 weeks</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Note:** Adapted with permission from Miller E, Shubrook JH. Role of the kidneys and sodium glucose co-transporter 2 (sGLT2) inhibitors in the treatment of type 2 diabetes mellitus. Osteopathic Family Physician. 2015.1(5):10–30. Copyright © 2015.

**Abbreviations:** EMPA, empagliflozin; F, female; GLIM, gliptin; GMIs, genital mycotic infections; M, male; MET, metformin; PBO, placebo; PIO, pioglitazone; SBP, systolic blood pressure; SU, sulfonylurea; UTI, urinary tract infection.

have been evaluated from pooled data from Phase I, II, and III studies in >11,000 patients. In that analysis, the overall incidence of volume depletion events was 1.4% with EMPA 10 mg and 1.5% with EMPA 25 mg vs 1.4% with placebo. The incidence of these events was higher in subjects aged ≥75 years, those with eGFR <30 mL/min/1.73 m², and those also receiving diuretic therapy.

Increased rates of hypoglycemia were not seen in EMPA monotherapy or in combination with insulin sensitizers. However, when combined with other medications that have a high risk of hypoglycemia (sulfonylureas or insulin), the EMPA arms of these studies had higher rates of hypoglycemia. This will need further investigation. Clinically, it may be important to pair SGLT2 inhibitors that counteract this increase in glucagon such as dipeptidyl-peptidase -4 inhibitor (DPP-4) inhibitors or glucagon like peptide 1 receptor agonist (GLP-1 RA).

**Empagliflozin/linagliptin-fixed dose combination**

Empagliflozin has been recently approved (February 2015) in a combination therapy with linagliptin (LINA) (a DPP-4 inhibitor). This medication, under the brand name Glyxambi® (Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA), is available as 10 mg EMPA/5 mg of LINA or 25 mg empagliflozin/5 mg of LINA. Boehringer Ingelheim manufactures both EMPA and LINA.

In a study, EMPA 25/LINA 5 mg (n=134) and EMPA/LINA 10 mg/5 mg (n=135) were utilized in drug-naïve type 2 diabetes with a baseline HbA1c of 7.99% and 8.04%, respectively. HbA1c improved by 1.08% (EMPA/LINA 25 mg/5 mg) and 1.24% (EMPA/LINA 10 mg/5 mg) and

**Recent updates**

**Empagliflozin and glucagon**

Ferrannini et al demonstrated that those people with type 2 diabetes who took an SGLT2 inhibitor had an increase in glucagon and hepatic glucose production. This has a potential explanation (that Bonner et al recently published) that there is SGLT2 expression in the α-cells in the pancreas.
Empagliflozin may play a role in the treatment of type 1 diabetes. A recent expert opinion paper summarized the potential use of SGLT2 inhibitors in patients with type 1 diabetes. Early studies have shown that use of SGLT2 inhibitors in type 1 diabetes can reduce HbA1c in 8 weeks by 0.4% in those with a baseline of 8.0%. Further, there was a statistical reduction in symptomatic hypoglycemia and total insulin dose. Mean urinary glucose excretion increased from 19 g/24 h to 134 g/24 h. Weight decreased by 2.7 kg, and there was also a reduction in waist circumference of 3.8 cm. There were two reported cases of diabetic ketoacidosis, but they were associated with a pump failure and an episode of gastroenteritis. This appears to be a significant finding that may be related to normoglycemia and relative insulinopenia. This is currently under further investigation.

Recently, it was shown that SGLT2 inhibition attenuated renal hyperfiltration in subjects with type 1 diabetes by affecting tubular glomerular feedback mechanisms and, potentially, by its effects on nitric oxide. Further study is needed to determine the safety and long-term efficacy of this medication in type 1 diabetes mellitus.

Clinical summary of EMPA

The SGLT2 inhibitors are a welcome addition to the diabetes treatment armamentarium. EMPA addresses hyperglycemia from a noninsulin centric manner, which can be complementary to other agents and can be used even in those who no longer make insulin. Further, EMPA appears to have significant nonglycemic benefits including weight loss, reduction in blood pressure, and reduction in uric acid. This is balanced by minor changes in lipid parameters and an increase in urinary tract and genital mycotic infections. While it was suspected by some physicians (including the authors of this paper) that glucosuria would result in ketoacidosis, but they were associated with a pump failure and an episode of gastroenteritis. This appears to be a significant finding that may be related to normoglycemia and relative insulinopenia. This is currently under further investigation.

Body weight reductions of 2.0 and 2.7 kg were seen. More people achieved an HbA1c of less than 7% at 24 and 52 weeks in the combination therapy than the individual medications.

This study group also completed a trial with fixed-dose EMPA/LINA as add-on to metformin. In this 52 week trial, subjects were randomized to EMPA/LINA 25 mg/5 mg (n=137), EMPA/LINA 10 mg/5 mg (n=136), or the individual medications, EMPA 25 (n=141), EMPA 10 mg (n=140), or LINA 5 mg (n=132). The fixed combinations had greater A1c reductions despite slightly lower starting A1c's. EMPA/LINA 25 mg/5 mg reduced A1c by 1.19%, and EMPA/LINA 10 mg/5 mg reduced A1c by 1.08%. The single agents reduced A1c 0.63%, 0.66%, and 0.7%, respectively. Weight loss was similar in the fixed combination groups and single agent EMPA. The 24-week weight loss was 3.0 kg in EMPA/LINA 25 mg/5 mg, 2.6 kg in EMPA/LINA 10 mg/5 mg, 3.2 kg in EMPA 25 mg, 2.5 kg in EMPA 10 mg, and 0.7 kg in LINA 5 mg.

Hypoglycemic risk and adverse reactions, such as urinary tract infections, pancreatitis, and cholesterol changes were monitored in the aforementioned trials. Results demonstrated that there was no increase in severe hypoglycemia even with the fixed dose combination. There was no increase or change in adverse reactions when these two medications were administered simultaneously vs their individual adverse reaction profiles.

Empagliflozin and renal indices

When the SGLT2 inhibitors were first released, there was some clinical concern that permissive glucosuria would contribute to advancing nephropathy despite some reassurance from the experience of people with familial renal glucosuria. In early clinical studies, there is some evidence that the contrary may be true. In a series of studies, patients with type 2 diabetes with preexisting microalbuminuria were randomized to EMPA 10, 25 mg, or placebo. Those on EMPA had reported decreased urinary albumin to creatinine ratio by 30% and 25%, respectively, compared to placebo.

Glucosuria. In early clinical studies, there is some evidence that despite permissive hyperglycemia, there may be some renoprotection from this class of medications. This suggests that despite permissive hyperglycemia, there may be some renoprotection from this class of medications. This is still exploratory and would need to be repeated.

Another study explored the effect of EMPA on the intraglomerular hemodynamic profile and hyperfiltration in patients with type 1 diabetes. In this study, 27 patients who had hyperfiltration but no hypertension or albuminuria, and 13 who had a normal GFR (and no hypertension/albuminuria) were given 8 weeks of EMPA 25 mg daily. The investigators found that there was an increase in renal afferent resistance in the hyperfiltrators with a reduction in glomerular hydrostatic pressure, but no change in renal efferent resistance. These parameters were not affected by EMPA in the normal GFR controls. This provides some evidence that EMPA could have some renoprotective effects and should be investigated further.
This is reflected by inclusion of this class of medications in the 2015 American Association of Clinical Endocrinologists treatment guidelines.\textsuperscript{56} While the role of these agents in type 1 diabetes is unclear, anecdotal reports suggest that when used carefully these agents have a significant clinical benefit in type 1 diabetes.

**Conclusion**

Empagliflozin (along with the other SGLT2 inhibitors) is a novel addition to treatment of type 2 diabetes. Empagliflozin has glycemic and nonglycemic benefits. Glycemic benefits are obvious with evidence based on lowering an HbA\textsubscript{1c} in an insulin-independent mechanism. Nonglycemic benefits include weight loss, blood pressure lowering, and decreased urinary protein excretion.

Diabetes is a progressive disorder, and combination therapy is expected as the disease progresses. Reducing the medication burden can help to improve adherence to complicated medication regimens. Glyxambi\textsuperscript{6} is a novel combination therapy option that includes new treatment pathways that do not rely on intact insulin secretion. Current guidelines recommend combination therapy early in type 2 diabetes therapy to address the variety of pathophysiologic mechanisms.\textsuperscript{51} Conversely, the cost of these agents may be prohibitive for some patients. Depending on drug coverage and generic availability, cost should be considered as increased cost could cause decreased adherence and disease management.

SGLT2 inhibitors may be seen in T2DM patients who have failed to reach HbA\textsubscript{1c} goals with single drug therapy with metformin and lifestyle changes. The use of SGLT2 inhibitors can be explored in patients who may need assistance with weight loss and potential improvement in blood pressure. They may be tried as an initial add-on to metformin or, in weight loss, or may be used after failure of a GLP-1. These should not be used in patients with renal failure, those at increased risk of candidiasis infections, or those at risk for hypotension.

In the future, SGLT2 inhibitors may be found in additional combination products. They may be found useful in patients with type 1 diabetes. Further studies are needed to explore further benefits or risks with SGLT2 inhibitors.

**Disclosure**

Jay H Shubrook has received research support from Sanofi and has served as a consultant to AstraZeneca, NovoNordisk and Eli Lilly. The authors report no other conflicts of interest in this work.

**References**


